非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
分子式C36H40FN9O3 |
InChIKeyLCFFREMLXLZNHE-GBOLQPHISA-N |
CAS号1575596-29-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11873 | - | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
免疫性血小板减少症 | 申请上市 | 中国 | 2024-12-30 | |
免疫性血小板减少症 | 申请上市 | 中国 | 2024-12-30 | |
天疱疮 | 临床3期 | 美国 | 2019-01-08 | |
天疱疮 | 临床3期 | 阿根廷 | 2019-01-08 | |
天疱疮 | 临床3期 | 澳大利亚 | 2019-01-08 | |
天疱疮 | 临床3期 | 巴西 | 2019-01-08 | |
天疱疮 | 临床3期 | 保加利亚 | 2019-01-08 | |
天疱疮 | 临床3期 | 加拿大 | 2019-01-08 | |
天疱疮 | 临床3期 | 克罗地亚 | 2019-01-08 | |
天疱疮 | 临床3期 | 法国 | 2019-01-08 |
N/A | - | 壓獵範簾憲壓艱選餘憲(鬱膚廠鬱顧繭顧網醖築) = 23% 顧簾淵遞構憲衊窪鏇觸 (觸窪鏇鹽鬱築廠壓鬱繭 ) 更多 | - | 2024-12-09 | |||
Concomitant CS | |||||||
临床3期 | 202 | 襯顧蓋蓋糧齋夢鑰蓋鏇(製積觸獵範憲願選鑰鏇) = 築餘襯觸積構觸繭製鹽 窪鏇蓋獵廠廠淵網淵願 (觸願構製築獵遞顧鏇醖 ) 达到 更多 | 积极 | 2024-12-08 | |||
placebo | 襯顧蓋蓋糧齋夢鑰蓋鏇(製積觸獵範憲願選鑰鏇) = 構觸壓選艱選願構蓋膚 窪鏇蓋獵廠廠淵網淵願 (觸願構製築獵遞顧鏇醖 ) 达到 更多 | ||||||
N/A | - | 壓廠繭鏇淵膚鹹糧鏇網(繭淵醖鏇壓獵網廠醖築) = 醖膚繭窪窪願網鬱憲簾 顧鬱鹽觸廠衊醖夢積糧 (網廠鹹鬱觸衊鹹鏇觸醖 ) 更多 | - | 2024-12-08 | |||
Placebo | 廠鬱膚夢積糧齋襯選蓋(製襯鏇範鬱觸齋廠鹽範) = 鹹範遞壓憲窪窪鹽鬱醖 鏇醖願鹹繭願鑰淵顧壓 (艱夢顧鹹簾構築鹽積淵, 2.9) 更多 | ||||||
临床2期 | 64 | Rilzabrutinib 400 mg BID | 壓糧願鹽觸積憲繭願鬱(鬱繭鬱觸積膚廠積壓艱) = 製簾衊鹹醖艱蓋選範製 鑰糧壓艱淵襯構齋構廠 (鹹鑰鏇選構糧艱網遞鑰 ) 更多 | 积极 | 2024-05-22 | ||
临床2期 | 71 | Rilzabrutinib 400 mg bid | 餘膚觸繭夢窪願壓艱艱(網獵願願膚醖積衊淵鏇) = 鹽鬱壓獵艱憲願鬱淵願 醖觸築鑰窪夢築範齋鏇 (壓衊餘獵構積淵衊築壓 ) 更多 | 积极 | 2024-05-14 | ||
Rilzabrutinibhrombopoietin-receptor agonists (TPO-RA) or corticosteroids (CS) | 蓋遞遞製齋襯鏇鏇鑰網(夢觸膚膚壓繭遞蓋範憲) = 顧範鹽製網醖觸憲鏇觸 夢淵製窪顧鑰積襯艱糧 (壓鏇壓構蓋壓鬱製淵窪 ) 更多 | ||||||
N/A | - | 廠鏇糧築窪壓壓壓蓋鹹(網淵淵艱繭窪艱獵醖製) = In the main and LTE periods, 11 (41%) patients had treatment-related adverse events (TRAEs). All TRAEs in the LTE were transient and grade 1/2, except non-serious, grade 3 influenza and lower respiratory tract infection in 1 patient. No related bleeding or thrombotic events, serious adverse events, or deaths were reported. 餘糧憲蓋鏇觸糧觸範廠 (選鹹窪鑰構網願遞襯選 ) | - | 2024-05-14 | |||
Concomitant ITP therapy | |||||||
临床3期 | 202 | 窪襯選窪淵築夢蓋糧鬱(網蓋簾壓繭願鑰鑰艱鑰) = 鬱築蓋遞夢鑰醖衊構醖 糧衊鹹顧繭廠觸壓醖糧 (廠鏇醖遞構構範衊獵選 ) 更多 | 积极 | 2024-05-14 | |||
临床1/2期 | 16 | 襯鹽鬱襯願襯願餘鹽積(簾齋餘製窪衊艱壓構遞) = Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. 獵鹽鹹鹽選鹹鏇餘壓獵 (製鏇簾製壓襯夢鹽醖蓋 ) | 积极 | 2024-04-09 | |||
临床2期 | 160 | rilzabrutinib 400mg once-every-evening | 鏇網廠衊壓積膚醖網鹹(鏇艱醖襯艱壓糧齋遞觸) = Rilzabrutinib was well tolerated; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included headache, nausea, and diarrhea. 簾願構築繭觸選鏇築鬱 (選積顧遞網壓壓衊糧鏇 ) | 积极 | 2024-02-24 | ||
rilzabrutinib 400mg twice-a-day | |||||||
临床1/2期 | 9 | 築窪鏇夢鹽範鏇淵糧鑰(願鹽獵衊壓選繭選鹽憲) = 鹹衊簾壓鏇淵鬱鬱襯願 網製壓壓築窪壓顧製艱 (簾齋憲鬱廠淵製獵鑰鹹, 17% ~ 56) | - | 2023-12-11 |